The presentation outlined WHO’s global strategy to eliminate cervical cancer, aiming for an incidence below four per 100,000 women through 90-70-90 targets by 2030. It traced the evolution of WHO guidelines (2011–2021), emphasizing HPV DNA testing, ablative treatments (cryotherapy, thermal ablation), and simplified screen-and-treat algorithms. Distinctions for women living with HIV include earlier and more frequent screening intervals. Emerging tools—mRNA testing, dual-stain cytology, AI, and self-sampling—are being reviewed under the “living guidelines” model for rapid evidence updates. Validation of HPV tests remains critical, as only 60% of 254 available assays have peer-reviewed evidence. Scaling up requires integration with reproductive health services, point-of-care solutions, and robust implementation research to ensure high coverage and treatment retention.